Galapagos NV's (GLPG) stock plunged in pre-market trading on Wednesday, October 31, 2024, after the biopharmaceutical company reported disappointing financial results for the third quarter of 2024.
The Belgian company reported a quarterly adjusted loss of $0.77 per share, missing analyst expectations of a loss of $0.49 per share. Revenue fell by a steep 50.1% year-over-year to €59.85 million, significantly lower than the consensus estimate of €69.44 million.
Galapagos' underperformance in the quarter, coupled with a 155.7% decline in analyst earnings estimates over the past three months, fueled concerns about the company's financial outlook. The pre-market sell-off reflects investors' disappointment with the company's failure to meet market expectations and the potential challenges it faces in the near future.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。